公开(公告)号：US11512115B2

公开(公告)日：2022-11-29

申请号：US16867650

申请日：2020-05-06

Applicant: Boehringer Ingelheim Vetmedica GmbH

Inventor： Annika Kraemer-Kuehl ,  Thomas Min Stephan ,  Hans-Christian Philipp

IPC: A61K39/00 ,  A61K39/215 ,  C12N7/00 ,  A61K39/12 ,  C07K14/165 ,  C07K14/005 ,  C12N15/85 ,  A61P31/14

Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.

公开(公告)号：US11224649B2

公开(公告)日：2022-01-18

申请号：US16665434

申请日：2019-10-28

Applicant: Boehringer Ingelheim Vetmedica GmbH

Inventor： Annika Kraemer-Kuehl ,  Hans-Christian Philipp

IPC: A61K39/215 ,  A61P31/14 ,  C12N7/00 ,  A61K39/00

Abstract: The present invention relates i.a. to a 4/91 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said 4/91 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

公开(公告)号：US11744888B2

公开(公告)日：2023-09-05

申请号：US17643293

申请日：2021-12-08

Applicant: Boehringer Ingelheim Vetmedica GmbH

Inventor： Annika Kraemer-Kuehl ,  Hans-Christian Philipp

IPC: A61K39/215 ,  A61P31/14 ,  C12N7/00 ,  A61K39/00

CPC classification number: A61K39/215 ,  A61P31/14 ,  C12N7/00 ,  A61K2039/5256 ,  A61K2039/552 ,  C12N2770/20021 ,  C12N2770/20022 ,  C12N2770/20034 ,  C12N2770/20071

Abstract: The present invention relates i.a. to a 4/91 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said 4/91 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

公开(公告)号：US11696947B2

公开(公告)日：2023-07-11

申请号：US16665465

申请日：2019-10-28

Applicant: Boehringer Ingelheim Vetmedica GmbH

Inventor： Annika Kraemer-Kuehl ,  Egbert Siegfried Mundt ,  Hans-Christian Philipp

IPC: A61K39/215 ,  C12N7/00 ,  A61P31/14 ,  A61K39/00

CPC classification number: A61K39/215 ,  A61P31/14 ,  C12N7/00 ,  A61K2039/5256 ,  A61K2039/552 ,  C12N2770/20021 ,  C12N2770/20022 ,  C12N2770/20034 ,  C12N2770/20071

Abstract: The present invention relates i.a. to an H52 IBV (infectious bronchitis virus) encoding for a heterologous S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said H52 IBV encoding for a heterologous S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

公开(公告)号：US11999766B2

公开(公告)日：2024-06-04

申请号：US18059171

申请日：2022-11-28

Applicant: Boehringer Ingelheim Vetmedica GmbH

Inventor： Annika Kraemer-Kuehl ,  Thomas Min Stephan ,  Hans-Christian Philipp

IPC: A61K39/215 ,  A61K9/00 ,  A61K39/00 ,  A61K39/12 ,  A61P31/14 ,  A61P37/04 ,  C07K14/005 ,  C12N7/00 ,  C12N15/85

CPC classification number: C07K14/005 ,  A61K39/215 ,  A61P31/14 ,  C12N7/00 ,  C12N15/85 ,  C12N2770/20022 ,  C12N2770/20023 ,  C12N2800/10

Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.

公开(公告)号：US11964999B2

公开(公告)日：2024-04-23

申请号：US18059171

申请日：2022-11-28

Applicant: Boehringer Ingelheim Vetmedica GmbH

Inventor： Annika Kraemer-Kuehl ,  Thomas Min Stephan ,  Hans-Christian Philipp

IPC: A61K39/215 ,  A61K9/00 ,  A61K39/00 ,  A61K39/12 ,  A61P31/14 ,  A61P37/04 ,  C07K14/005 ,  C12N7/00 ,  C12N15/85

CPC classification number: C07K14/005 ,  A61K39/215 ,  A61P31/14 ,  C12N7/00 ,  C12N15/85 ,  C12N2770/20022 ,  C12N2770/20023 ,  C12N2800/10

Abstract: The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.